Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells
Clinical Immunology · 2024-12 · 269 · 110402
DOI: 10.1016/j.clim.2024.110402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Immunology, 2024-12. Verfasst von Ritis Kumar Shyanti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Department of Biological Sciences, Alabama State University, AL 36104, USA. Hauptthemen laut MEDLINE: Antigens, CD1d, Natural Killer T-Cells, Neoplasms, Antigen-Presenting Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Science Foundation, National Institutes of Health.
Abstract (Originalsprache)
Two major antigen processing pathways represent protein Ags through major histocompatibility complexes (MHC class I and II) or lipid Ags through CD1 molecules influence the tumor immune response. Invariant Natural Killer T cells (iNKT) manage a significant role in cancer immunotherapy. CD1d, found on antigen-presenting cells (APCs), presents lipid Ags to iNKT cells. In many cancers, the number and function of iNKT cell are compromised, leading to immune evasion. Additionally impaired motility of iNKT cells may contribute to poor tumor prognosis. Emerging evidences suggest that CD1d, itself also influences cancer progression. Patient databases further highlight the importance of CD1d expression in different cancers and its correlation with patient survival outcomes. The ability of iNKT cells to activate and enhance the immune response renders them an attractive target for cancer immunotherapy. This review discusses all the possible ways of cancer immune evasion and restoration of immune responses mediated by CD1d-iNKT interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Center, Department of Biological Sciences, Alabama State University, AL 36104, USA.
- Microbiology, Biochemistry, and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA, USA.
- Cancer Research Center, Department of Biological Sciences, Alabama State University, AL 36104, USA. Electronic address: mmishra@alasu.edu.
Förderung
- NIA NIH HHS
- National Science Foundation
- National Institutes of Health
- American Cancer Society
- Foundation for the National Institutes of Health
Zitieren
APA
Shyanti, R. K., Haque, M., Singh, R., & Mishra, M. (2024). Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells. Clinical Immunology, 269, 110402. https://doi.org/10.1016/j.clim.2024.110402
Vancouver
Shyanti RK, Haque M, Singh R, Mishra M. Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells. Clinical Immunology. 2024;269:110402. doi:10.1016/j.clim.2024.110402
BibTeX
@article{Shyanti2024,
author = {Shyanti, Ritis Kumar and Haque, Mazharul and Singh, Rajesh and Mishra, Manoj},
title = {Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells},
journal = {Clinical Immunology},
year = {2024},
volume = {269},
pages = {110402},
doi = {10.1016/j.clim.2024.110402}
}
EUVIMED